Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In-Class immunotherapies
Source: finanznachrichten.de